-
公开(公告)号：US20210187033A1
公开(公告)日：2021-06-24
申请号：US17092107
申请日：2020-11-06
Applicant: NOVARTIS AG
Inventor： Anthony Edward Boitano , Michael Cooke , Shifeng Pan , Peter G. Schultz , John Edward Tellew , Yongqin Wan , Xing Wang
IPC: A61K35/28 , A61K38/00 , C07D487/04 , C12N5/0789 , C07D473/34 , C07D473/16 , C07D495/04 , A61K9/00 , A61K31/52
Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
-
公开(公告)号：US10787480B2
公开(公告)日：2020-09-29
申请号：US16439204
申请日：2019-06-12
Applicant: NOVARTIS AG
Inventor： Bernhard Hubert Geierstanger , Jan Grunewald , Yunho Jin , Weijia Ou , Tetsuo Uno , Yongqin Wan , Xing Wang
Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
-
公开(公告)号：US20170239296A1
公开(公告)日：2017-08-24
申请号：US15409292
申请日：2017-01-18
Applicant: NOVARTIS AG
Inventor： Anthony E. Boitano , Michael Cooke , Shifeng Pan , Peter G. Schultz , John Tellew , Yongqin Wan , Xing Wang
IPC: A61K35/28 , A61K9/00 , C12N5/0789 , A61K31/52
CPC classification number: A61K35/28 , A61K9/0019 , A61K31/52 , A61K38/00 , A61K2035/124 , C07D473/16 , C07D473/34 , C07D487/04 , C07D495/04 , C12N5/0647 , C12N2501/38 , C12N2501/60
Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
-
公开(公告)号：US20180155281A1
公开(公告)日：2018-06-07
申请号：US15822930
申请日：2017-11-27
Applicant: NOVARTIS AG
Inventor： Bernhard Hubert Geierstanger , Jan Grunewald , Weijia OU , Shifeng Pan , Tetsuo Uno , Yongqin Wan , Xing Wang
IPC: C07D207/09 , C07D401/12 , A61K47/68 , C07K16/32 , C07D403/12 , C07D403/14 , C07D413/12
CPC classification number: C07D207/09 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6855 , C07D401/12 , C07D403/12 , C07D403/14 , C07D413/12 , C07K5/0205 , C07K16/32
Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
-
公开(公告)号：US20160263113A1
公开(公告)日：2016-09-15
申请号：US15070905
申请日：2016-03-15
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: A61K31/506 , A61K31/4184
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
Patent Agency Ranking
公开(公告)号：US10392421B2
公开(公告)日：2019-08-27
申请号：US15961531
申请日：2018-04-24
Applicant: NOVARTIS AG
Inventor： Bernhard Hubert Geierstanger , Jan Grunewald , Yunho Jin , Weijia Ou , Tetsuo Uno , Yongqin Wan , Xing Wang
Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
-
公开(公告)号：US20160120866A1
公开(公告)日：2016-05-05
申请号：US14994827
申请日：2016-01-13
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: A61K31/506 , A61K31/4184 , A61K9/00
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
公开(公告)号：US10280139B2
公开(公告)日：2019-05-07
申请号：US15822930
申请日：2017-11-27
Applicant: NOVARTIS AG
Inventor： Bernhard Hubert Geierstanger , Jan Grunewald , Weijia Ou , Shifeng Pan , Tetsuo Uno , Yongqin Wan , Xing Wang
IPC: C07D207/09 , C07K5/02 , A61K47/68 , C07D401/12 , C07D403/12 , C07D403/14 , C07D413/12 , C07K16/32
Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
-
公开(公告)号：US20160280687A1
公开(公告)日：2016-09-29
申请号：US15179644
申请日：2016-06-10
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: C07D403/04 , C07D401/14 , C07D405/14
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
公开(公告)号：US20160280686A1
公开(公告)日：2016-09-29
申请号：US15179385
申请日：2016-06-10
Applicant: Novartis AG
Inventor： Shenlin Huang , Xianming Jin , Zuosheng Liu , Daniel Poon , John Tellew , Yongqin Wan , Xing Wang , Yongping Xie
IPC: C07D403/04 , C07D405/14 , C07D401/14
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.027 seconds)
